As of quarter end, Invesco Global Opportunities Fund was well-balanced across 180 small- and mid-cap stocks from around the world, with approximately 60% of the fund invested in the US and 37% across non-US. The largest sector overweights compared to the benchmark were industrials at +6.4% and financials at -5.3%. During the quarter, we added and removed several stocks to reflect our desired po...
Data analytics firm Verisk said on Monday it had pulled the plug on its planned $2.35 billion acquisition of AccuLynx, which makes software for roofing contractor.
JERSEY CITY, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, announced today that it has terminated its definitive agreement to purchase AccuLynx.
KYND cyber intelligence integrates into Verisk's Rulebook, as new KYND research reveals 80 percent of the UK's top retailers are vulnerable to cyber threats KYND cyber intelligence integrates into Verisk's Rulebook, as new KYND research reveals 80 percent of the UK's top retailers are vulnerable to cyber threats
The Top 15 High-Growth Dividend Stocks for December 2025 offer a 1.58% yield and 20.97% five-year dividend growth, appearing 33% undervalued. The watchlist's goal is a 12% long-term CAGR, with November gains moving closer to this target despite trailing SPY and VIG year-to-date. Quality and Value tilts are tested for superior returns, with the Value portfolio showing higher yields and the Quali...
For the quarter, Voya MidCap Opportunities Strategy Fund outperformed the Index on a NAV basis due largely to favorable stock selection. Key contributors to performance included Kratos Defense & Security Solutions, Inc. (KTOS), Comfort Systems USA, Inc. (FIX), and AppLovin Corp (APP). Key detractors from performance included MoonLake Immunotherapeutics (MLTX), Tradeweb Markets, Inc. (TW), and V...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.